Estimation of the costs attributable to vitamin K antagonist treatment in patients with non-valvular atrial fibrillation from a French societal perspective

• Váldodahkkit: Pierre Levy (Dahkki), David M. Smadja (Dahkki), Julie Dorey (Dahkki), Mondher Toumi (Dahkki), Anna-Katharina Meinecke (Dahkki), Kevin Bowrin (Dahkki), Jean-Baptiste Briere (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: Taylor & Francis Group, 2019-01-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

Background: Little is known about the costs associated with vitamin K antagonist (VKA) treatment in patients with non-valvular atrial fibrillation (NVAF) in France. Objectives: To evaluate monthly per-patient costs attributable to VKA treatment in NVAF patients from a French societal perspective. St...